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Phosphodiesterases in non-neoplastic
appearing colonic mucosa from patients
with colorectal neoplasia
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Mattias Salling Dahllöf2, Steen Seier Poulsen2, Niels Bindslev2 and Mark Berner Hansen1,3
Abstract
Background: Intracellular signaling through cyclic nucleotides, both cyclic AMP and cyclic GMP, is altered in
colorectal cancer. Accordingly, it is hypothesized that an underlying mechanism for colorectal neoplasia involves
altered function of phosphodiesterases (PDEs), which affects cyclic nucleotide degradation. Here we present an
approach to evaluate the function of selected cyclic nucleotide-PDEs in colonic endoscopic biopsies from
non-neoplastic appearing mucosa.
Methods: Biopsies were obtained from patients with and without colorectal neoplasia. Activities of PDEs were
characterized functionally by measurements of transepithelial ion transport and their expression and localization
by employing real-time qPCR and immunohistochemistry.
Results: In functional studies PDE subtype-4 displayed lower activity in colorectal neoplasia patients (p = 0.006).
Furthermore, real-time qPCR analysis showed overexpression of subtype PDE4B (p = 0.002) and subtype PDE5A
(p = 0.02) in colorectal neoplasia patients. Finally, immunohistochemistry for 7 PDE isozymes demonstrated the
presence of all 7 isozymes, albeit with weak reactions, and with no differences in localization between colorectal
neoplasia and control patients. Of note, quantification of PDE subtype immunostaining revealed a lower amount
of PDE3A (p = 0.04) and a higher amount of PDE4B (p = 0.02) in samples from colorectal neoplasia patients.
Conclusion: In conclusion, functional data indicated lower activity of PDE4 subtypes while expressional and
abundance data indicated a higher expression of PDE4B in patients with colorectal neoplasia. We suggest that
cyclic nucleotide-PDE4B is overexpressed as a malfunctioning protein in non-neoplastic appearing colonic mucosa
from patients with colorectal neoplasia. If a predisposition of reduced PDE4B activity in colonic mucosa from
colorectal neoplasia patients is substantiated further, this subtype could be a potential novel early diagnostic
risk marker and may even be a target for future medical preventive treatment of colorectal cancer.
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Background
Colorectal cancer (CRC) is a major global health problem
and has one of the lowest survival rates for all types of
cancers [1]. Colorectal neoplasia (CRN) is correlated with
the development of CRC [2].
The pathogenesis and etiology of CRC and CRN are still
not fully understood. With regards to CRC, non-steroidal
anti-inflammatory drugs (NSAIDs) decrease mortality rate
and inhibit de novo disease development. The exact mech-
anism by which NSAIDs exert their anticarcinogenic ef-
fect is not completely understood [3, 4]. Investigators
attribute part of the anticancer activity of NSAIDs to their
inhibition of the cyclooxygenase (COX) enzymes, leading
to a decrease in activity of prostaglandins and cyclic ad-
enosine monophosphate (cAMP) [5, 6].
Recently some COX-independent targets have been
identified as being involved in the anticancer effects
of NSAIDs [3, 7–10]. Moreover, both cAMP and cyc-
lic guanosine monophosphate (cGMP) phosphodies-
terases (PDEs) have gained particular interest in
relation to CRN [3, 11, 12]. PDEs are metallophoshy-
drolases which specifically hydrolyzes the 3′,5′-cyclic
phosphate moiety in cyclic nucleotides (cNTs) to a
non-cyclic 5′ monophosphate, thereby deactivating
cAMP and cGMP. PDE activity terminates second
messenger signaling by degrading cNTs, whereas in-
hibition of PDE activity blocks cNT hydrolysis to
mimic or amplify cNT signaling. The PDE superfamily
consists of 20 distinct genes divided into 11 protein
families, PDE1-11 [13].
Studies on human colon cancer cell lines show de-
creased levels of cGMP and elevated levels of PDE5
mRNA [3, 14], indicating a perturbed activity of the PDEs
involved in degrading cGMP in CRC. Similar studies have
been conducted investigating the role of cAMP in CRC
[4]. However, studies in cancer cell lines, show conflicting
outcomes regarding the role of prostaglandins, cAMP and
cGMP in CRN and CRC pathogenesis [15–20].
In order to identify a potential predisposition in
colonic mucosa for development of CRN in non-
neoplastic colon, we decided to study the function, ex-
pression and localization of several PDE subtypes in
specimens of endoscopically non-neoplastic appearing
colonic mucosa.
Methods
Aim
The aim of this study was to investigate function, ex-
pression and localization/abundance of selected PDEs in
biopsies from non-neoplastic appearing colonic mucosa
obtained from patients with and without CRN. Thus,
questioning if a possible predisposition to the cancer dis-
ease exists in non-neoplastic appearing colonic mucosa.
Study population
Patients referred for a colonoscopy on suspicion of CRC,
were included and divided into two groups. The first
group consisted of patients with present or history of
CRN, while the second group was control patients (i.e.
CTRL) with no present or history of CRN. Patients with
incomplete colonoscopy, hemorrhagic diathesis, and in-
flammatory bowel disease or with previous sigmoid resec-
tion were excluded from the study. A total of 27 subjects
were enrolled, hereof 12 CRN-subjects (4 women) and 15
CTRLs (7 women). For each patient, we noted age, body
mass index (BMI), previous illnesses, medication, all signs
of earlier colorectal disease and the findings during the
colonoscopy. Age and BMI were well balanced between
groups. Mean age (±SEM) for CTRL patients was 58 ± 3.7
and for CRN patients 66 ± 3.7 years. Mean BMI was 24.9
± 1.5 in CTRL patients and 26.2 ± 0.9 in CRN patients.
Eight patients from the CTRL and 6 patients from the
CRN group had comorbidities such as ischemic heart
disease, heart failure, hypertension, atrial fibrillation,
diabetes, kidney failure, chronic obstructive lung disease,
dyslipidemia, intermittent claudication, peptic ulcer dis-
ease, osteoporosis, rheumatic arthritis, polycystic ovary
syndrome and pacemaker implantation. There were no
apparent differences between the two groups in comor-
bidity. Eight patients in the CTRL group and 8 patients
in the CRN group were using regular medications e.g. anti-
thrombotic, ACE inhibitors, statins, levothyroxine, proton
pump inhibitors, angiotensin II receptor antagonists,
glucocorticoids, β-blockers, β-agonists, anti-histamines,
xanthine oxidase inhibitors, diuretics, antifolate and anti-
emetics. There were no apparent differences between the
two groups in prescribed medications. None of the drugs
has a direct effect on the PDE metabolism.
Ethics
The Scientific Ethical Committee of Copenhagen
(H32013107) and The Danish Data Protection Agency
approved the study protocol (BBH-2013-024, I-Suite no:
02342). The study was conducted by the Helsinki declar-
ation. All patients participating gave written informed
consent.
Biopsy extraction and processing
Six biopsies from each patient were obtained during en-
doscopy from non-neoplastic appearing colonic mucosa
using standard biopsy forceps (Boston Scientific, Radial
Jaw 4, outside diameter of 2.2 mm). Biopsies were ob-
tained approximately 30 cm orally from the anal verge
and at least 10 cm from endoscopically abnormal tissue
(i.e. neoplasia). The biopsies were immediately transferred
to an iced, oxygenized bicarbonate Ringer solution with
the following composition (in mM): Na+ (140), Cl− (117),
K+ (3.8), PO4
3− (2.0), Mg2+ (0.5), Ca2+ (1.0), glucose (5.5)
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and HCO3
− (25). Before obtaining biopsies, the media pH
was adjusted to 7.4 by gassing with 95% O2/5% CO2.
Chemicals
Theophylline, indomethacin, acetazolamide, zaprinast,
cilostamide, rolipram, cAMP and cGMP were purchased
from Sigma-Aldrich (Seelze, Germany). Sildenafil, db-
cAMP, cGMP, and antibodies for PDE3B (cat. no.: SC-
376823), PDE4A (cat. no.: SC-74428), PDE4B (cat. no.:
SC-25812), PDE4D (cat. no.: SC-25097) and PDE5A (cat.
no.: SC-32884) were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Antibodies for PDE3A
(cat. no.: LS-A732) and PDE4C (cat. no.: LS-C185777)
were purchased from LifeSpan BioSciences, Inc. (Seattle,
WA, USA). Primer sequences were synthesized by TAG-
Copenhagen (Copenhagen, Denmark). The human PDE10
real-time PCR primers were purchased from Qiagen.
Bumetanide was obtained from Leo Pharmaceuticals
(Copenhagen, Denmark). All other chemicals were of ana-
lytical grade.
Pretreatment
Up to 4 biopsies from each patient were mounted in
Mini-Ussing-Air-Suction-Chambers (MUAS chambers)
for measuring transepithelial electrolyte transport cap-
tured as short circuit currents (SCC). The method used
has previously been described in detail [21, 22]. Correc-
tion for media resistance between tips of potential elec-
trodes was carried out just before mounting of biopsies,
thus circumventing challenges of edge damage in meas-
uring correct active ion transport. The time between
the biopsy procedure and mounting of up to 4 biopsies
into MUAS chambers was about 45 min during which
the samples were kept in oxygenated-Ringer solution at
approximately 0 °C. Following approximately 15 min of
equilibration, baseline SCC and slope conductance
values were recorded. Amiloride (20 μM) was subse-
quently added to the luminal side of the MUAS chamber
to inhibit epithelial sodium channels and thereby reducing
cell energy expenditure. Indomethacin (13 μM) was added
to the basolateral side to inhibit endogenous synthesis of
cNTs. Experiments were resumed after an additional
20 min equilibration period. If stable SCC was not
achieved during pretreatment, the biopsy was excluded
from further study.
Cyclic-AMP-related PDEs and inhibitors
In one part of our functional study, db-cAMP (16 μM)
was applied on the basolateral side of biopsies. After
10 min, biopsies were then exposed to cilostamide (PDE3
inhibitor, 1 μM) or rolipram (PDE4 inhibitor, 1 μM).
PDE3 and PDE4 primarily degrade cAMP [23, 24], and
their inhibition elicited a rise in SCC. Then a dose of
theophylline (400 μM, added bilaterally), a competitive
and nonselective PDE-inhibitor raising intracellular levels
of cNT [25], was applied to give maximal inhibition of
PDE activity and maximal cNT-induced SCC. Finally each
experiment was terminated after adding bumetanide
(25 μM), ouabain (200 μM) and acetazolamide (250 μM),
alone or in combination to the basolateral side of the
biopsies.
Cyclic-GMP investigation
In a second part of the functional study, cGMP (16 μM)
was applied to biopsies. Previous reports have provided
data showing more consistent responses when cGMP is
applied vs db-cGMP [21]. After 10 min, samples were
exposed to sildenafil (1 μM) or zaprinast (1 μM), both
PDE5 and PDE10 inhibitors [26]. However, when no
changes in SCC were observed, concentrations were in-
creased stepwise to reach a final concentration of max-
imally 500 μM for the inhibitors and 50 μM for cGMP.
Each experiment was terminated following the basolateral
addition of bumetanide (25 μM), ouabain (200 μM) and
acetazolamide (250 μM), alone or in combination.
RNA extraction from biopsies
One biopsy from each patient was obtained for RNA-
analysis. The mean wet weight of each biopsy was
5.8 mg. Thus we were only able to perform qPCR on a
selected number of PDE isoforms. Biopsies were imme-
diately transferred to RNA Later (Life Technologies,
Naerum, Denmark). Biopsies were homogenized using
a TissueLyser II (Qiagen, Copenhagen, Denmark), and
RNA was extracted using NucleoSpin RNA® (Macherey-
Nagel, Düren, Germany). RNA concentration and pur-
ity were determined using a NanoDrop® ND-1000
(NanoDrop Technologies, Wilmington, DE, USA),
and the latter as the A260/A280 and A260/A230 absorb-
ance ratios.
cDNA synthesis
RNA was converted to cDNA using the iScript™ cDNA
Synthesis Kit (BioRad, Copenhagen, Denmark) according
to the manufacturers protocol.
Primer design
Primers against genes of interest and against β-actin
[21] were designed using Primer3 (http://frodo.wi.
mit.edu/primer3/input.htm) based on sequences obtained
from Ensembl (http://www.ensembl.org/). The primer se-
quences were synthesized by TAGCopenhagen (Copenhagen,
Denmark): PDE3A forward (5′-CAGAGTGAATCCCGT
CACTTC-3′) reverse (5′-TGGTCCAAGTGGAAGAAAC
TC-3′); PDE3B forward (5′-TATGATCACCCAGGGAG
GAC-3′) reverse (5′-GTTGTATTCTGGGCGAGAAAG-3′);
PDE4A forward (5′-TGAAGACCGATCAAGAA
GAGC-3′) reverse (5′-GTAATCCGACACGCAAAAG
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AT-3′); PDE4B forward (5′-ATCTCACGCTTTGGA
GTCAAC-3′) reverse (5′-TTAAGACCCCATTTGTTC
AGG-3′); PDE4C forward (5′-GCGATATCTTCCAG
AACCTCA-3′) reverse (5′-CTTGTCACCTTCTTGGT
CTCC-3′); PDE4D forward (5′-TTTCACGGTGGCA
CATACAT-3′) reverse (5′-GTGGACAAAATTTGCTT
GGAG-3′); PDE5A forward (5′-TTGTGCAGAACT
TCCAGATGA-3′) reverse (5′-TTTAGAGCAGCAAA
CATGCAC-3′); β-Actin forward (5′-ACCCAGCAC
AATGAAGATCA-3′) reverse (5′-CGTCATACTCCTG
CTTGCTG-3′).
Dilution series of cDNA from HEK293 cells were run to
verify acceptable amplification efficiencies and specificities
by standard and dissociation curves for all primer sets.
qPCR analysis
cDNA was amplified on a 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA) using
Fast SYBR® Green Master Mix (Applied Biosystems) by
the manufacturer’s manual. All samples were run in tripli-
cates with β-actin primers on all plates. Results were ana-
lysed using SDS 2.3 (Applied Biosystems), and expression
was calculated by the 2-ΔCT method.
Immunohistochemical localization and quantification
One colon biopsy from each patient was put aside in 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4),
embedded in paraffin, and cut into 4 μm sections.
Sections were boiled in citric buffer (pH 6 or 9) in a
microwave oven for 15 min, followed by preincubation
in 2% BSA for 10 min, and overnight incubation at 4 °C
with primary antibodies. Subsequently, the sections were
incubated for 40 min with biotinylated secondary anti-
body immunoglobulins, followed by a preformed avidin
and biotinylated horseradish peroxidase macromolecular
complex (code number PK-4000; Vector Laboratories)
for 30 min. Three percent hydrogen peroxide was added
after the second antibody layer. Finally, 3,3-diaminoben-
zidine (KEM-EN-TEC, catalog number 4170) was added
for 15 min, followed by a 2 min incubation in 0.5%
copper sulfate (Merck; catalog number 2790) diluted in
Tris buffer containing 0.05% Tween 20. Counterstaining
was performed with Mayer’s hemalun.
Images for quantification were recorded using a Zeiss
Axioplan 2 plus microscope (Jena, Germany) fitted with
a Photometrics CoolSNAP camera (Tucson, AZ, USA)
and analysis was performed using Image-Pro Plus 7.0
software. A quantification of coloring was performed by
to blinded investigators as a marker for protein abundance
in biopsies (Nctrl = 7, NCRN = 8). Images for quantification
were recorded at 20x magnification and the area measured
represented 176000 μm2 of tissue. The area of stained
structures was measured by selecting a colored region
of interest. Automatically, areas with same color were
measured - one image from each biopsy was measured.
Mean ± SEM for samples in each group were calculated.
Images for localization were recorded using a Zeiss
Axio10 Imager A1 microscope (Jena, Germany) fitted with
a Zeiss AxioCam ICc 3 camera (Jena, Germany) and
analysis was performed using Image-Pro 9.1 software.
Only mucosal layers were analyzed.
Statistical analysis
Values are expressed as the mean ± SEM. The mean value
was calculated and used when identical experiments were
performed on several biopsies from the same patient. The
statistical significance of differences between two groups
was tested using Student’s t-test, provided that the vari-
ances of the groups were similar. For functional data, the
Mann–Whitney U-test was applied in the case of unequal
variance. For qPCR data, data with unequal variance were
log transformed. When the variance of log transformed
data was unequal, the Mann–Whitney U-test was applied.
In qPCR experiments, when calculating statistics for
Fig. 1 Short circuit current in biopsies from a control patient (a) and
a CRN patient (b). The rolipram-induced increase in SCC observed in
CTRLs (a) is not observed in CRN-patients (b). Biopsies mounted in
the MUAS chambers were exposed to: amiloride (20 μM), indomethacin
(13 μM), theophylline (100 μM), bumetanide (25 μM) and
ouabain (200 μM)
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multiple groups, one-way ANOVA with Tukey’s multiple
comparisons test was used. A p-value less than 0.05 were
considered statistically significant. Statistical analysis was
done using SigmaPlot 12.3 for Windows, Systat Software
Inc. (USA/Canada).
Results
Functional characterization of PDE activity
CTRL patients responded to rolipram (1 μM) with higher
SCC increases compared to CRN patients (p = 0.006)
(Figs. 1 and 2). This increase in SCC was 64% higher in
CTRL patients (Fig. 2). No significant change was ob-
served in SCC when samples, after prestimulation with
db-cAMP, were exposed to either cilostamide (1 μM),
(p = 0.869) or sildenafil (1 μM), (p = 0.899). No changes
in SCC were recorded at even the highest concentra-
tions of sildenafil or zaprinast. All biopsies presented
an increase in SCC when exposed to theophylline. A
decrease was observed when bumetanide and oubain were
applied at the end of experiments, verifying the viability of
samples to elicit a response. Up to 4 biopsies from each
patient were successfully mounted in the MUAS cham-
bers. At baseline mean SCC (±SEM) for CTRL and CRN
patients was 68.2 ± 12.6 μA/cm2 and 78.2 ± 24.9 μA/cm2.
During the observation period, slope conductance ranged
between 36 and 150 mS⋅cm−2. To better understand the
functional connection between SCC, PDE activity and
cNT activity and inhibition, we present a simplified model
(Fig. 3).
PDE expression
All 8 investigated PDEs were detected in biopsies by
qPCR. Normalized to ß-actin levels, a significantly
higher expression was measured for PDE4B and PDE5A
in biopsies from CRN patients compared with CTRLs
(Fig. 4). Expression level of PDE4B was 78% higher in
Fig. 2 PDE inhibitor induced increase in SCC. Rolipram gave a significantly larger inhibition in CTRL- compared to CRN-patients, whereas, sildenafil
and cilostamide showed no significant difference. Control patients: rolipram 12.7 ± 1.4 (N = 11, n = 11), sildenafil 6.6 ± 1.2 (N = 9, n = 9) cilostamide
64.9 ± 3.0 (N = 11, n = 13). Neoplasia patients: rolipram 8.1 ± 0.7 (N = 10, n = 10), sildenafil 6.4 ± 0.8 (N = 8, n = 8), cilostamide 61.9 ± 5.1 (N = 11, n = 12).
Changes presented as mean SCC ± SEM. * Indicates a statistical difference. *p < 0.05
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CRN patients (p = 0.002), and PDE5A had a 49% higher
expression level in the same group (p = 0.02). PDE3A had
an expression level more than 10 fold greater than all
other investigated PDEs (p < 0.0001), both in CRN and
CTRL patients (Fig. 4). The expression of PDE4D showed
a tendency of higher expression in CRN patients (p =
0.0712) (Fig. 4). No differences in expression levels of
PDE10A were measured when comparing normal colonic
mucosa from both CRN and CTRL patients (p = 0.6), the
generated dataset is available as Additional file 1.
Immunohistochemistry
Examination of PDE3A-B, PDE4A-B-C-D and PDE5A in
15 biopsies was conducted at different tissue sections for
each PDE. Consistent with all tissues sections and all ex-
amined biopsies, N = 7 for CTRL patients and N = 8 for
CRN patients, our investigation revealed that all 7 PDE
subtypes are present in normal appearing human sig-
moidal mucosa. Figure 5 shows examples of biopsy speci-
mens as measured by immunohistochemical staining with
antibodies. The distribution of the isoenzymes locations
varied. The PDE3A-antibody stained both epithelial and
underlying cells in connective tissue, in a manner that
indicated a non-specific reaction. Staining for PDE4B was
specific for epithelial cells, while its localization at a sub-
cellular level could not be determined.
Blinded quantification of specific coloring in immunohis-
tochemical biopsies revealed a difference between CTRL
patients and CRN patients for PDE3A, 11 403 ± 1209 vs.
8313 ± 762 (p = 0.035), and for PDE4B, 4276 ± 640 vs.
6723 ± 724 (p = 0.019), respectively. No difference was ob-
served for PDE3B, PDE4A, PDE4C, PDE4D and PDE5A
(Table 1). All included biopsy specimens predominantly
contained epithelial cells and underlying connective tissue.
In specific, no smooth muscle cells were observed.
Discussion
Choice of tissue
Many studies conducted with cancer cell lines have eval-
uated the importance of PDEs, although most studies
only examined one or a few PDE subtypes. The general
conclusion from these studies is, yes PDEs are perturbed
in transformed cells or tissues [27, 28].
Of note, to our knowledge, there are no studies on the
importance of PDE subtypes in non-neoplastic colonic
mucosa obtained from patient with CRN.
Our study of PDEs provides support for a CRN predis-
position with both perturbed activities of PDE4 and of
Fig. 3 Basic mechanism of cyclic nucleotide regulation and function. This cartoon shows basic synthetic and regulatory pathways for cAMP and
cGMP. P indicates decreased levels in colorectal neoplasia and C marks increased levels in colorectal neoplasia. *Enzymes with perturbed function
in colorectal neoplasia. pGC, particulate guanylyl cyclase; pAC, particulate adenylyl cyclase; sGC, soluble guanylyl cyclase; sAC, soluble adenylyl
cyclase; NO, nitric oxide; HCO3, bicarbonate; PDE, phosphodiesterase; Cl
−, chloride ion
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expression of PDE4B and PDE5A subtypes likely involved
in regulatory functions of normal colonic mucosa.
PDE families selected
Based on a review of the literature, we selected 3 families
of the PDE superfamily, PDE3, PDE4, and PDE5 to be
evaluated. For members of each of these PDE families, 3
aspects were studied – their activity, although indirectly
by SCC, expression by employing qPCR, and tissue
localization by immunohistochemistry. Whilst collecting
data for our study a publication by Li N et al., Oncogene,
reported elevated expression levels of PDE10A in both
colon tumor cell lines and clinical tumor specimens.
Therefore we conducted an additional q-PCR run examin-
ing expression levels of PDE10A in our normal appearing
colonic mucosa from patients with CRN and compared it
to CTRL. Expression levels of all the remaining PDE
subtypes must await later studies, but is relevant to exam-
ine to fully asses the role of the entire PDE-family.
SCC as a measure of PDE activity
Two key intracellular signaling molecules in enterocytes
are cAMP and cGMP [29] and their activity is dependent
on cNT-PDE activity. Using the SCC as a measure of
PDEs activity is based on the knowledge that these en-
zymes hydrolyze both cAMP and cGMP, and that both
these two second messengers are intracellular inducers of
anion secretion in colonic mucosa as shown in earlier
studies [21], (Fig. 3). Therefore, in normal tissue from
patients with and without CRN, PDE function can be
measured indirectly by the size of recorded SCC sensitive
to PDE inhibitor drugs.
Abnormal levels of either cAMP or cGMP are shown to
play a potentially pivotal role in initiating cancer develop-
ment and for its progression or abrogation [3, 4, 30–32].
Fig. 4 Expression levels for PDEs. Expression of subtypes PDE4B and PDE5A was significantly higher in the CRN patient group. For controls in
PDE5A (N = 4, n = 4), PDE4B (N = 5, n = 5), PDE4D (N = 5, n = 5). For neoplasia in PDE5A (N = 5, n = 5), PDE4B (N = 8, n = 8), PDE4D (N = 8, n = 8).
Expression levels are relative to ß-actin. Data presented as means ± SEM. *p < 0.05 and **p < 0.01
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PDE enzymes are important regulators of the intracellular
level of the mentioned cNTs, as their hydrolysis by PDEs
by far exceeds their non-stimulated synthesis. Thus for
instance, under basal conditions the intracellular concen-
tration of cAMP is typically kept at less than 5 pmol per
mg protein [33].
Sensitivity of PDE activity, expression and localization
Although it may be argued that use of enzymatic assays
and Western blots would be more direct approaches to
measurements of PDE activity and abundance than SCC
and qPCR, the latter methods carry advantages. Both
SCC and qPCR are by far more sensitive and yield much
higher accuracy than enzymatic assays and Western
blots. For instance, the SCC technique has a sensitivity
of measuring changes in ion movement in the range of
pmol per second, equal to changes of 0.1 μampere. No
ELISA kit can match that. Moreover, the SCC is directly
related to the PDE activity located in epithelial cells,
elegantly circumventing activity in other locations of the
A
B C D
E F G
Fig. 5 Immunohistochemical staining of endoscopic biopsy. Staining for A, PDE3A; B, PDE4A; C, PDE3B; D, PDE4C; E, PDE4B; F, PDE4D; G, PDE5A.
All images are acquired at objective magnification of 40x
Table 1 Immunohistochemical quantification data
PDE subtype Sample Size,
CTRL vs CRN
Mean (±SEM)
CTRL vs CRN
p-value
PDE3A 14 vs 16 11404 (1209) vs 8313 (762) 0.035
PDE3B 14 vs 16 4098 (829) vs 4200 (908) 0.936
PDE4A 14 vs 16 16740 (1997) vs 13786 (1203) 0.203
PDE4Ba 14 vs 16 4276 (640) vs 6723 (724) 0.019
PDE4C 14 vs 16 16954 (1458) vs 15439 (1159) 0.418
PDE4D 14 vs 15 8473 (1442) vs 6923 (936) 0.369
PDE5A 14 vs 16 16614 (1514) vs 14736 (1365) 0.363
Only PDE4B elicited significantly altered expression and quantification levels.
P-values for PDE3A and PDE3B were calculated using Mann–Whitney rank test.
All other p-values were obtained using the students t-test. A sample from the
CRN group was removed for PDE4D after both blinded investigator concluded
that quantification was not possible
aMarks PDE subtypes with significantly elevated expression levels
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studied tissue. Immunohistochemistry has an advantage
over Western blotting by the visualizing location of
specific proteins, sometimes even revealing subcellular
positions, while often with a near equal sensitivity in the
abundance of studied proteins compared with Western
blots.
Levels of PDE activity
Rolipram is a selective inhibitor of PDE4 family members.
The response of SCC to rolipram was significantly larger
in biopsies from CTRLs compared to CRNs. As PDE4 en-
zymes primarily hydrolyze cAMP, the result of rolipram-
sensitive SCC indicates a reduced elimination of cAMP
and reduced control with this signaling pathway in normal
colonic mucosa from CRN patients.
The SCC response to cilostamide showed no difference
in activity of the PDE3 family of enzymes in non-
neoplastic appearing colonic mucosa between patient
groups. Meanwhile, the change in SCC due to cilostamide
as an inhibitor was on average three times larger than that
of rolipram, see results. The balancing control effect of
cellular PDE on cNT signaling is thus dominated by PDE3
family members.
Surprisingly, we did not find any SCC-sensitive activity
of PDE5 in the biopsy material, despite applying high con-
centrations of potent inhibitors. An explanation for this
lack of activity is low levels of basal intracellular cGMP
concentration and failure to introduce significant amounts
of cellular cGMP by our basolateral exogenous application
of cGMP. Furthermore, applied PDE5 inhibitors sildenafil
and zaprinast might not be inhibitors of PDE5 in whole
human colonic epithelia tissue. In cell line studies, zapri-
nast was found not to be a specific PDE5 inhibitor, while
specific effects of rolipram, a PDE4 inhibitor, were de-
tected [28]. In contrast to our findings, Li et al. presented
a study in which sulindac sulfide was able to inhibit cGMP
PDE, including PDE5, in cancer cell lines [34]. The same
study also documented inhibitory effects of sildenafil on
colon tumor cells. However sulindac sulfide is not an ef-
fective inhibitor of colonic PDE5 in whole biopsies and
could not be used in our study setting according to manu-
facturer. So far, the functional role of PDE5 in the devel-
opment of CRN in man remains unresolved and further
studies are warranted.
Expression of PDEs
Our expressional study detected PDE subtypes 3A, 3B,
4A, 4B, 4C, 4D, 5A and 10A, with PDE3A as the domin-
ant PDE isoform in normal colonica mucosa in both
CRN patients and CTRL patients. Nucleotide expression
data from a cancer cell line published by Tsukahara
et al. suggests PDE3B, and not PDE3A as the main PDE
isoform [35]. This is in direct contrast to our findings.
In their study, they did not detect any mRNA for
PDE3A. Several possible explanations exist for this appar-
ent discrepancy, such as the employed human cancer cell
lines did not express PDE3A. This PDE3A and PDE3B
discrepancy is another good argument for studying tissue
from patients and not just cell lines. A study by Li N. et al.
found elevated expression levels of PDE10A in colon
tumor cell lines and clinical specimens from colon tumors
[36]. We did an additional q-PCR run to examine if this
was the case in normal colonic mucosa as well. The same
primer was used as in the original study; however, there
were no significant differences in expression levels be-
tween CRN and CTRL patients. This indicates that ex-
pression levels of PDE10A rise when a macroscopic
change is seen in the colonic mucosa.
We detected a significantly higher expression of PDE4B
in the CRN patients, which has not been previously
described in man. Meanwhile, our data on rolipram-
sensitive SCC clearly show a lower activity of PDE
isozymes in biopsies from CRN patients (Fig. 2), while data
on PDE4B from neighboring tissues in the same CRN pa-
tients point to both an increased expression (Fig. 4), and
an augmented abundance of protein (Fig. 5). Thus, the
lower activity of PDE4 detected in functional experiments
on CRN-biopsies contradicts the observations of increased
tissue expression and abundance of PDE4B: implicating a
higher activity of PDE4s. However, there is a simple and
likely explanation for the discrepancy between functional
and expressional data. The CRN disease might produce a
non-functional PDE4B protein with a disease-induced fru-
gal compensatory elevation of its mRNA and protein. This
also corroborates the observed higher basal SCC in CRN-
biopsies, see Results. Of course, this explanation calls for a
future closer look, in which a combination of transcription,
translation and post-translation processing of PDE4B and
its function is required. A lesson from this part of our
study is that determination of protein expression ought to
be combined with protein processing and function.
The literature describes PDE5A as overexpressed in
breast and colon tumor cells while the expression of other
cGMP PDE isozymes is decreased [3, 37]. Our study con-
firmed that expression levels of PDE5A are increased in
CRN patients, which previous studies describe in various
cancer cell lines [37, 38]. Our primers were specifically de-
signed to detect mRNA in colon epithelia. We did not take
into account splicing and genetic variants of respective
PDEs and therefore further studying of these is required.
In general, PDE isozymes and their expression in normal
colonic tissue is not well described in the literature [39].
Immunohistochemical localization and quantification of
PDEs
Immunohistochemical analysis confirmed that our qPCR
was performed on epithelial cells specimens as no under-
lying nerve and muscle tissue were detected.
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Before the start of our study we conducted a search of
the literature, which indicated that immunostaining for
PDE3A-B, PDE4A-B-C-D and PDE5A often lacked im-
ages demonstrating the precision of the antibodies and
with very few reports on the topic. We used several of
the most recommended antibodies for each PDE. In our
material/methods and result sections we present the best
antibodies of those employed after consulting with sev-
eral manufacturers of the PDE antibodies.
We found that antibodies for PDE3A especially and
most of the used antibodies were not specifically local-
ized to colonic epithelial cells as underlying connective
tissue cells showed high immunoreactivity as well. This
result, therefore, demands further research for a better
antibody for PDEs in human colonic epithelia.
In regards to PDE5A our findings suggest that it can
be seen in normal appearing epithelia while most studies
so far have only observed PDE5 in smooth musculature
in normal tissue [40]. One study shows that no signaling
was observed in the healthy colonic epithelium. How-
ever, it was present in cancerous tissue aspiring from co-
lonic epithelia [3]. Further studies are therefore required
before it can be concluded that PDE5 is found in normal
colonic epithelia.
During our immunohistochemical studies, we employed
manual microscopic quantification to assess the abun-
dance of PDEs as a surrogate marker for protein abun-
dance in biopsies. The technique has some drawbacks
as described in the literature [41]. Most of the disadvan-
tages are due to inter-observer differences. We attempted
to overcome this by blinding two investigators and stand-
ardizing assessment protocols. In spite of taking the
abovementioned reservations into account the results
from the quantification provide an incentive for further
investigation into the abundance of PDEs in colonic tissue
from patients with CRN and to validate the IHC results. A
future investigative modality could be Western blot to ver-
ify our finding.
Furthermore, the abundance of PDE5A was lower in
CRN compared to controls, but this result was not signifi-
cant (Table 1.) In contrast q-PCR data showed an elevated
level of PDE5A mRNA. Since the result was not signifi-
cant for the immunohistochemical abundance quantifica-
tion there is not much to conclude from this. However, if
the results described were significant the discrepancy
could be attributed to e.g. perturbed translation of the
PDE5A mRNA resulting in lower levels of PDE5A enzyme
or that produced protein is malformed and therefore not
functioning optimally.
Conclusion
In light of recent reports in the neoplastic cell, we
aimed to outline the role of the most prominent PDEs
in normal appearing colonic mucosa from patients with
CRN. We sought to investigate the function, expression
and localization of PDE subtype 3, 4 and 5 in biopsies.
PDE10 was investigated with qPCR only. Our data sug-
gests that PDE4B activity is not only dysregulated in CRN
per se but also dysregulated in normal appearing mucosa
of patients with CRN. In specific PDE4 subtypes could
potentially serve as promising pharmacological targets
for diagnostic and therapeutic interventions for CRN, al-
though a robust data-driven scientific rationale for select-
ing PDE4 or any other subtype remains to be challenged
and explored accordingly. Furthermore, expression levels
of PDE5A are elevated in normal appearing colonic mu-
cosa from patients with CRN, however no differences
were observed for this PDE with regards to activity or pro-
tein abundance.
Additional file
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